{"url_path":"/sec/aim/8-k/2026-08-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-036996-index.html","accession_number":"0001493152-26-036996","cik":"0000946644","ticker":"AIM","issuer_name":"AIM ImmunoTech Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-036996-index.html","primary_entity_key":"0000946644","primary_entity_name":"AIM ImmunoTech Inc."},"word_count":440,"has_tables":true,"body_markdown":"**Item 7.01**\n**Regulation\nFD Disclosure.**\n\n \n\nOn\nAugust 11, 2026, the online media company *Breaking Defense* (https://breakingdefense.com)\npublished an article authored by Thomas K. Equels, the Chief Executive Officer of AIM ImmunoTech Inc. (the “Company”). The\narticle, titled “Biodefense is force protection: Ready today, prepared for tomorrow,” discusses the importance of military\nforce readiness, specifically how the Company’s drug Ampligen (rintatolimod) has potential as a broad-spectrum early-onset and/or\nprophylactic antiviral therapeutic for Ebola virus disease. The article also discusses Ampligen’s history and potential as a broad-spectrum\nearly-onset and/or prophylactic antiviral therapeutic in the treatment of COVID-19 and related viruses. A copy of the article is furnished\nas Exhibit 99.1 hereto.\n\n \n\nThe\ninformation furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18\nof the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any\nfiling under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.\n\n \n\n**Cautionary\nNote Regarding Forward-Looking Statements**\n\n \n\nThis\nCurrent Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements within the meaning of Section 27A of the Securities\nAct of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but\nare not limited to, statements relating to: the potential of Ampligen as a broad-spectrum prophylactic or early-onset treatment for viral\nthreats, including Ebola virus disease and coronaviruses; preclinical proof-of-concept findings, which are not evidence of FDA approval\nor clinical efficacy in humans; expectations regarding Ampligen’s mechanism of action; the timing and outcome of future clinical\ntrials, regulatory submissions, or government funding decisions; and the Company’s business strategy and objectives.\n\n \n\nWords\nsuch as “believe,” “may,” “will,” “could,” “should,” “estimate,”\n“anticipate,” “intend,” “expect,” “potential,” “plan,” “project”\nand similar expressions identify forward-looking statements. These statements are based on current expectations and assumptions that\nmay prove incorrect, and involve risks and uncertainties that could cause actual results to differ materially. Important factors include:\nuncertainties in pharmaceutical development, including the risk that preclinical results may not be replicated in clinical trials; regulatory\nuncertainties; dependence on government funding; limited financial resources; and competitive and market conditions.\n\n \n\nFor\nadditional risk factors, see the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC at\nwww.sec.gov. All forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to update\nthem except as required by law. The Company claims the protection of the safe harbor for forward-looking statements contained in the\nPrivate Securities Litigation Reform Act of 1995."}